Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • Journal club
  • Alerts
  • Subscriptions

Precision medicine in COPD: review of mepolizumab for eosinophilic COPD

Gabriella Long, Jasmine Wall
Breathe 2018 14: 338-341; DOI: 10.1183/20734735.026318
Gabriella Long
University of Manchester, Manchester University Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabriella Long
  • For correspondence: gabriella.long@postgrad.manchester.ac.uk
Jasmine Wall
Bolton NHS Foundation Trust, Bolton, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jasmine Wall
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 14 no. 4 338-341
DOI 
https://doi.org/10.1183/20734735.026318

Published By 
European Respiratory Society
Print ISSN 
1810-6838
Online ISSN 
2073-4735
History 
  • Published online November 30, 2018.

Copyright & Usage 
Copyright ©ERS 2018 Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

Author Information

  1. Gabriella Long1⇑ and
  2. Jasmine Wall2
  1. 1University of Manchester, Manchester University Foundation Trust, Manchester, UK
  2. 2Bolton NHS Foundation Trust, Bolton, UK
  1. E-mail: gabriella.long{at}postgrad.manchester.ac.uk
View Full Text

Article usage

Article usage: November 2018 to November 2019

AbstractFullPdf
Nov 20180101
Dec 20182453116
Jan 2019512936
Feb 201938336
Mar 201966521
Apr 201934924
May 201946020
Jun 201953513
Jul 201943214
Aug 20195225
Sep 20191397
Oct 20193307
Nov 201953413

Altmetrics

PreviousNext
Back to top
Vol 14 Issue 4 Table of Contents
Breathe: 14 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
Gabriella Long, Jasmine Wall
Breathe Dec 2018, 14 (4) 338-341; DOI: 10.1183/20734735.026318

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
Gabriella Long, Jasmine Wall
Breathe Dec 2018, 14 (4) 338-341; DOI: 10.1183/20734735.026318
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Introduction
    • Study design
    • Key results
    • Strengths and limitations
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Expert opinion

  • Could airway basal cells be a novel predictor of mortality in IPF?
  • Can biomarkers guide antibiotic treatment in COPD exacerbations?
  • EGFR mutation status in lung cancer
Show more Expert opinion

Journal club

  • Could airway basal cells be a novel predictor of mortality in IPF?
  • Can biomarkers guide antibiotic treatment in COPD exacerbations?
  • EGFR mutation status in lung cancer
Show more Journal club

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2019 by the European Respiratory Society